Anna V Cartwright, Hannah Krzyzanowski, Rona Moss-Morris, Laura Smith, Yogini Sawjani, Camilla Böhme Kristensen, Nuvera Mukaty, Sam Norton, Jo Armes, Colette R Hirsch
{"title":"一种新的数字干预(“FRAME”)促进原发性乳腺癌治疗妇女恢复能力的可行性随机对照试验","authors":"Anna V Cartwright, Hannah Krzyzanowski, Rona Moss-Morris, Laura Smith, Yogini Sawjani, Camilla Böhme Kristensen, Nuvera Mukaty, Sam Norton, Jo Armes, Colette R Hirsch","doi":"10.1002/pon.70217","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the acceptability of a novel Cognitive Bias Modification for Interpretation (CBM-I) intervention, 'FRAME', to promote resilience in women who have completed active treatment for primary breast cancer and determines the feasibility of a full-scale randomised controlled trial.</p><p><strong>Methods: </strong>A two-armed, participant-blind, parallel groups randomised controlled trial of CBM-I versus a time-matched control. Participants were recruited from community organisations and social media. Measures of acceptability, feasibility, change in interpretation bias and clinical outcomes (resilience, mood and quality of life) were assessed at baseline (T0), 1-month post-randomisation (T1, end of intervention), 2-month (T2) and 4-month post-randomisation (T3).</p><p><strong>Results: </strong>Sixty-seven participants completed baseline assessment and were randomised to the FRAME CBM-I (n = 35) or control group (n = 32). Acceptability of CBM-I met pre-specified progression criteria, and 80% adhered to the CBM-I intervention. Between-group differences in interpretation bias at T1 demonstrated a moderate effect in favour of CBM-I on two measures of interpretation bias (SMD<sub>g</sub> = 0.66 and 0.73). Effect size estimates suggest moderate treatment effects on resilience (SMD<sub>g</sub> = 0.64) and small effects on mood, in favour of FRAME. No intervention-related adverse events were reported.</p><p><strong>Conclusions: </strong>The study results provide strong support for the acceptability of a new online CBM-I intervention ('FRAME') to promote resilience in women treated for primary breast cancer and indicate that a full-scale trial is feasible. The study fulfiled all pre-specified progression criteria to advance to an efficacy trial, except meeting the recruitment target of 70 participants. Importantly, recruitment took place during the Covid-19 pandemic. Recommendations for future research are provided.</p>","PeriodicalId":20779,"journal":{"name":"Psycho‐Oncology","volume":"34 7","pages":"e70217"},"PeriodicalIF":3.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240892/pdf/","citationCount":"0","resultStr":"{\"title\":\"Feasibility Randomised Controlled Trial of a New Digital Intervention ('FRAME') to Promote Resilience in Women Treated for Primary Breast Cancer.\",\"authors\":\"Anna V Cartwright, Hannah Krzyzanowski, Rona Moss-Morris, Laura Smith, Yogini Sawjani, Camilla Böhme Kristensen, Nuvera Mukaty, Sam Norton, Jo Armes, Colette R Hirsch\",\"doi\":\"10.1002/pon.70217\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study investigates the acceptability of a novel Cognitive Bias Modification for Interpretation (CBM-I) intervention, 'FRAME', to promote resilience in women who have completed active treatment for primary breast cancer and determines the feasibility of a full-scale randomised controlled trial.</p><p><strong>Methods: </strong>A two-armed, participant-blind, parallel groups randomised controlled trial of CBM-I versus a time-matched control. Participants were recruited from community organisations and social media. Measures of acceptability, feasibility, change in interpretation bias and clinical outcomes (resilience, mood and quality of life) were assessed at baseline (T0), 1-month post-randomisation (T1, end of intervention), 2-month (T2) and 4-month post-randomisation (T3).</p><p><strong>Results: </strong>Sixty-seven participants completed baseline assessment and were randomised to the FRAME CBM-I (n = 35) or control group (n = 32). Acceptability of CBM-I met pre-specified progression criteria, and 80% adhered to the CBM-I intervention. Between-group differences in interpretation bias at T1 demonstrated a moderate effect in favour of CBM-I on two measures of interpretation bias (SMD<sub>g</sub> = 0.66 and 0.73). Effect size estimates suggest moderate treatment effects on resilience (SMD<sub>g</sub> = 0.64) and small effects on mood, in favour of FRAME. No intervention-related adverse events were reported.</p><p><strong>Conclusions: </strong>The study results provide strong support for the acceptability of a new online CBM-I intervention ('FRAME') to promote resilience in women treated for primary breast cancer and indicate that a full-scale trial is feasible. The study fulfiled all pre-specified progression criteria to advance to an efficacy trial, except meeting the recruitment target of 70 participants. Importantly, recruitment took place during the Covid-19 pandemic. Recommendations for future research are provided.</p>\",\"PeriodicalId\":20779,\"journal\":{\"name\":\"Psycho‐Oncology\",\"volume\":\"34 7\",\"pages\":\"e70217\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240892/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psycho‐Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pon.70217\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psycho‐Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pon.70217","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Feasibility Randomised Controlled Trial of a New Digital Intervention ('FRAME') to Promote Resilience in Women Treated for Primary Breast Cancer.
Objective: This study investigates the acceptability of a novel Cognitive Bias Modification for Interpretation (CBM-I) intervention, 'FRAME', to promote resilience in women who have completed active treatment for primary breast cancer and determines the feasibility of a full-scale randomised controlled trial.
Methods: A two-armed, participant-blind, parallel groups randomised controlled trial of CBM-I versus a time-matched control. Participants were recruited from community organisations and social media. Measures of acceptability, feasibility, change in interpretation bias and clinical outcomes (resilience, mood and quality of life) were assessed at baseline (T0), 1-month post-randomisation (T1, end of intervention), 2-month (T2) and 4-month post-randomisation (T3).
Results: Sixty-seven participants completed baseline assessment and were randomised to the FRAME CBM-I (n = 35) or control group (n = 32). Acceptability of CBM-I met pre-specified progression criteria, and 80% adhered to the CBM-I intervention. Between-group differences in interpretation bias at T1 demonstrated a moderate effect in favour of CBM-I on two measures of interpretation bias (SMDg = 0.66 and 0.73). Effect size estimates suggest moderate treatment effects on resilience (SMDg = 0.64) and small effects on mood, in favour of FRAME. No intervention-related adverse events were reported.
Conclusions: The study results provide strong support for the acceptability of a new online CBM-I intervention ('FRAME') to promote resilience in women treated for primary breast cancer and indicate that a full-scale trial is feasible. The study fulfiled all pre-specified progression criteria to advance to an efficacy trial, except meeting the recruitment target of 70 participants. Importantly, recruitment took place during the Covid-19 pandemic. Recommendations for future research are provided.
期刊介绍:
Psycho-Oncology is concerned with the psychological, social, behavioral, and ethical aspects of cancer. This subspeciality addresses the two major psychological dimensions of cancer: the psychological responses of patients to cancer at all stages of the disease, and that of their families and caretakers; and the psychological, behavioral and social factors that may influence the disease process. Psycho-oncology is an area of multi-disciplinary interest and has boundaries with the major specialities in oncology: the clinical disciplines (surgery, medicine, pediatrics, radiotherapy), epidemiology, immunology, endocrinology, biology, pathology, bioethics, palliative care, rehabilitation medicine, clinical trials research and decision making, as well as psychiatry and psychology.
This international journal is published twelve times a year and will consider contributions to research of clinical and theoretical interest. Topics covered are wide-ranging and relate to the psychosocial aspects of cancer and AIDS-related tumors, including: epidemiology, quality of life, palliative and supportive care, psychiatry, psychology, sociology, social work, nursing and educational issues.
Special reviews are offered from time to time. There is a section reviewing recently published books. A society news section is available for the dissemination of information relating to meetings, conferences and other society-related topics. Summary proceedings of important national and international symposia falling within the aims of the journal are presented.